Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.06 +1.23%

+$0.04 today

Market cap
$227.58M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 4.13M

Average 3.33M

CABA Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Cabaletta Bio, Inc.NASDAQ: CABA

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $337K fell 30.5% year over year, behind the -16.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.2% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -30.5% toward the trailing-twelve-month pace of -16.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$337K-3.2% QoQ
Last fiscal yearDec 2025
$1.65M-3.8% YoY
LTMMar 2026
$1.5M-16.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.5%——
1 year-3.8%——
3-year CAGR+11.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
1.65M USD
Year-over-year change
-3.8%
4-year CAGR
+22.4%

Depreciation & Amortization vs competitors

How CABA compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -16.9% is the 9th highest of 11, against a peer median of -0.4%.
  • Over three fiscal years its annual growth of +11.8% compares with a peer median of +3.0%.
CABA Competitors
Depreciation & Amortization for CABA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1B USD+66925.2%+52.5%—
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$12.13M USD-8.0%-4.7%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$10.43M USD-42.2%-13.8%33645.2%
HUMAHumacyte, Inc.LTM Mar 2026$7.3M USD+0.4%-3.6%362.3%
EDITEditas Medicine, Inc.LTM Mar 2026$3.84M USD-39.2%-5.9%9.9%
PRQRProQR Therapeutics N.V.LTM Mar 2026€2.72M EUR-0.9%+1.0%20.3%
IMMPImmutep LimitedFY2025A$2.13M AUD+6.0%+5.1%42.3%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$2.12M USD+4.8%+22.0%—
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$1.65M USD-13.9%+19.6%—
CABACabaletta Bio, Inc.LTM Mar 2026$1.5M USD-16.9%+11.8%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$416K USD+0.0%+17.0%—
Peer median (excluding CABA) —-0.4%+3.0%42.3%

Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development32.49M39.3M55.42M97.2M142.67M
Selling, General & Admin13.82M14.84M19.24M27.94M29.57M
Operating Expenses46.31M54.14M74.66M125.14M172.24M
Depreciation & Amortization733K1.18M1.43M1.71M1.65M
EBITDA(45.56M)(51.8M)(66.25M)(113.41M)(164.21M)
EBITDA Margin—————
Operating Income(46.31M)(54.14M)(74.66M)(125.14M)(172.24M)
Operating Margin—————
Interest Income24K1.16M6.99M10.03M6.03M
Interest Expense000748K2M
Other Income / Expenses24K1.16M6.99M9.28M4.39M
Income Before Tax(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Net Margin—————
EPS (Basic)(1.80)(1.81)(1.65)(2.34)(1.64)
EPS (Diluted)(1.80)(1.81)(1.65)(2.34)(1.64)
Weighted Avg Shares25.74M29.34M40.95M49.52M102.26M
Weighted Avg Shares (Diluted)25.74M29.34M40.95M49.47M102.26M

Cabaletta Bio, Inc.

NASDAQ:CABA

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.